Standard BioTools Inc. (NASDAQ:LAB) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Michael Egholm - Chief Executive Officer and President Vikram Jog - Chief Financial Officer Operator Hello, and welcome to the Standard BioTools Inc. Third Quarter 2022 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeNardo, Investor Relations. Thank you, Mr. DeNardo. Y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of ...

Unleashing tools to accelerate breakthroughs in human health SECOND QUARTER 2022 FINANCIAL RESULTS AUGUST 8, 2022 Standard BioTools Forward-looking statements L e g a l I n f o r m a t i o n This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding operational and strategic plans, revenue growth and business transformation expectations, potential acquisi ...

Standard BioTools Inc. (NASDAQ:LAB) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Peter DeNardo – Investor Relations Michael Egholm – Chief Executive Officer and President Vikram Jog – Chief Financial Officer Conference Call Participants Operator Hello, and welcome to the Standard BioTools Incorporated Second Quarter 2022 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Peter DeNardo, Inve ...

| --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | REFINITIV STREETEVENTS EDITED TRANSCRIPT LAB.OQ - Q1 2022 Standard BioTools Inc Earnings Call EVENT DATE/TIME: MAY 05, 2022 / 9:00PM GMT | | | REFINITIV STREETEVENTS \| www.refinitiv.com \| Contact Us | | ©2022 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ _____________________________________________ Securities registered pu ...

Standard Bitola Inc. (NASDAQ:LAB) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Peter DeNardo – Investor Relations Michael Egholm – Chief Executive Officer and President Vikram Jog – Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the Standard BioTools Inc. First Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ (Exact name of registrant as specified in its charter) Delaware 77-0513190 State or other jurisdiction of incorporation or organization I.R.S. Employer Identification No. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 Address of principal executive offices Zip Code FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal yea ...

Financial Highlights - Q4 revenue reached $38.3 million[11] - Q4 product and service margin was 52.7% (GAAP) and 61.8% (Non-GAAP)[11] Market Opportunities and Growth - The total addressable market is estimated to be approximately $7 billion[17] - The total addressable market is projected to grow to approximately $9 billion by 2025[18] - Multiplex Proteomics is estimated to have a CAGR of ~8% from 2020-2025[19] - Next-Gen Sequencing Library Prep is estimated to have a CAGR of ~14% from 2020-2025[19] - Midthroughput Molecular Diagnostics is estimated to have a CAGR of ~9% from 2020-2025[19] - Mass Cytometry market is growing at 10%-plus[25] Market Penetration - Academia and Medical Centers: 19% penetrated today, targeting 30% penetration by 2025[27] - Pharma/Biotech: 8% penetrated today, targeting 30% penetration by 2025[27] - CROs: 1% penetrated today, targeting 10% penetration by 2025[27] - Hospitals/Reference Labs: 0% penetrated today, targeting 5% penetration by 2025[27]

Financial Data and Key Metrics Changes - Total revenue for Q3 2021 was $28.5 million, down from $39.9 million in Q3 2020, primarily due to lower COVID-19 revenue and development grants [18] - Base product and service revenue, excluding COVID-19 testing, was $25.6 million, slightly up from $25.1 million year-over-year [18] - GAAP net loss for Q3 2021 was $13.8 million compared to $6 million in Q3 2020, while non-GAAP net loss was $5.4 million compared to a net income of $2.5 million in the prior year [22][23] Business Line Data and Key Metrics Changes - Mass cytometry product and service revenue was $15.8 million, up 5% from Q3 2020 [19] - Microfluidics product and service revenue was $12.1 million, down 40% year-over-year, primarily due to a $7.9 million decline in COVID testing revenue [19] - Service revenue was $6 million, slightly down from $6.1 million in the same period last year [19] Market Data and Key Metrics Changes - Revenue from the Americas declined by 45% to $13 million, driven by lower COVID testing revenue [21] - EMEA revenue grew 14% to $10.1 million, primarily due to improved mass cytometry instrument sales [21] - Asia-Pacific revenue decreased by 27% to $5.4 million, impacted by tax exemption delays in China and lockdowns in Japan [21] Company Strategy and Development Direction - The company is focusing on a three-part strategy: innovation, partnerships, and beachhead expansion [5] - The launch of the Biomark X instrument is part of the strategy to integrate existing technologies and expand market reach [8] - The Board of Directors is reviewing strategic alternatives to maximize stockholder value, including costs and capital structure [7] Management's Comments on Operating Environment and Future Outlook - Management noted that supply chain issues have impacted the ability to fulfill orders, with a backlog of over $9 million [5] - The outlook for the near term is tempered by supply chain reliability concerns [6] - Full-year guidance for total revenue is revised to approximately $123 to $127 million, reflecting ongoing challenges [27] Other Important Information - The company has completed its commitments under the DARPA agreement, recognizing $600 thousand in revenue [22] - The public website has been re-platformed to enhance e-commerce efficiency and distributor relationships [17] Q&A Session Summary - No specific questions or answers were provided in the transcript, as the call concluded with a thank you from management [29]